Trademark: 79223972
Word
ONCOSIGNATURE
Status Date
Tuesday, April 9, 2019
Registration Number
5718472
Registration Date
Tuesday, April 9, 2019
Filing Date
Friday, September 22, 2017
Published for Opposition
Tuesday, January 22, 2019
5 Pharmaceutical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; medical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; veterinary pharmaceutical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; pharmaceutical and medical preparations for treatment, prevention and alleviation of cancer; pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; biological preparations for medical and veterinary purposes, namely, for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, specifically in oncology and premalignant disorders and benign tumors; chemical preparations for therapeutic use, namely, for pharmaceutical or medical purposes, namely, for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; reagents for medical use, namely, for medical diagnosis, drug-tailored efficacy prediction and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits and does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes
42 Scientific and technological research and consultation services, namely, in the medical, pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, and identification of rational drug combinations; industrial analysis and research services, namely, industrial research in the field of oncology; basic medical research and medical clinical research, hereunder for development of therapeutics; drug discovery services; consultancy in the field of pharmaceutical research and development; medical and scientific research related to cancer and cancer therapy, including research related to treatment, prevention and alleviation of cancer; pharmaceutical research services related to prediction of drug treatment efficacy; medical research services related to cancer diagnosis, cancer prognosis and drug-tailored efficacy prediction; medical research, namely, analysis related to cancer diagnosis, cancer prognosis and drug-tailored efficacy prediction
The mark consists of the stylized wording "ONCOSIGNATURE" with "ONCO" in orange and "SIGNATURE" in blue. Above the wording are two interlocked circles, each consisting of an outer border of small blue circles and an inner layer of larger orange circles.
The color(s) orange and blue is/are claimed as a feature of the mark.
Apr 9, 2024
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Feb 26, 2022
Change Of Owner Received From Ib
Jul 13, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Jul 13, 2021
Teas Change Of Correspondence Received
Jul 13, 2021
Teas Change Of Domestic Representatives Address
Jul 13, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Jul 13, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jul 13, 2021
Teas Change Of Owner Address Received
Aug 16, 2019
Final Decision Transaction Processed By Ib
Jul 31, 2019
Final Disposition Notice Sent To Ib
Jul 31, 2019
Final Disposition Processed
Jul 9, 2019
Final Disposition Notice Created, To Be Sent To Ib
Apr 9, 2019
Registered-Principal Register
Jan 25, 2019
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 25, 2019
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jan 25, 2019
Notification Processed By Ib
Jan 22, 2019
Official Gazette Publication Confirmation E-Mailed
Jan 22, 2019
Published For Opposition
Jan 9, 2019
Notification Of Possible Opposition Sent To Ib
Jan 9, 2019
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 2, 2019
Notification Of Notice Of Publication E-Mailed
Dec 17, 2018
Approved For Pub - Principal Register
Dec 13, 2018
Examiner's Amendment Entered
Dec 13, 2018
Notification Of Examiners Amendment E-Mailed
Dec 13, 2018
Examiners Amendment E-Mailed
Dec 13, 2018
Examiners Amendment -Written
Aug 27, 2018
Assigned To Examiner
Aug 3, 2018
Teas/Email Correspondence Entered
Aug 3, 2018
Correspondence Received In Law Office
Aug 2, 2018
Assigned To Lie
Jul 18, 2018
Teas Response To Office Action Received
Feb 3, 2018
Refusal Processed By Ib
Jan 18, 2018
Non-Final Action Mailed - Refusal Sent To Ib
Jan 18, 2018
Refusal Processed By Mpu
Jan 6, 2018
Non-Final Action (Ib Refusal) Prepared For Review
Jan 6, 2018
Application Filing Receipt Mailed
Jan 5, 2018
Non-Final Action Written
Jan 2, 2018
Assigned To Examiner
Jan 2, 2018
New Application Office Supplied Data Entered
Dec 28, 2017
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
